Could a natural hormone help tame a common heart rhythm disorder?

NCT ID NCT07359872

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This early-stage trial tests whether relaxin, a natural hormone given as a daily injection, can reduce the burden of atrial fibrillation (AF) in 208 veterans who have not responded to standard medications and are scheduled for catheter ablation. The study aims to see if relaxin can counteract harmful electrical changes in the heart caused by oxidative stress, potentially lowering AF recurrence after the procedure. It is a Phase 1/2 study, meaning it is primarily evaluating safety and early effectiveness.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Relaxin (a naturally occurring hormone given as a daily injection)

What this could lead to

If it works, this could point toward a new treatment to reduce atrial fibrillation recurrence after standard ablation procedures.

What could go wrong

This is an early Phase 1/2 trial with only 208 participants, so results may not apply broadly. The treatment is still experimental and may not prove effective or safe.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEART FAILURE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Arrhythmias, Cardiac atrial fibrillation cardiac rhythm disease heart failure stroke disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-••••